Heparin Induced Thrombocytopenia
Heparin Induced Thrombocytopenia (9892-08)
Discuss the antibody implicated in Heparin Induced Thrombocytopenia (HIT), along with clinical findings and laboratory assays. This course covers the clinical features, mechanism, detection methods and treatment of HIT including a short historical perspective and review of heparin.
PEP hours: 16
CPS credits: 1.1
Course Type: Express
Start Date: Upon registration
Completion: Up to 52 weeks
Delivery: PDF via email
Equipment: Computer with Internet is required
- Describe the mode of action, clinical response and monitoring of unfractionated heparin.
- Contrast and compare low molecular weight heparin with unfractionated heparin.
- Describe briefly the early historical discoveries that have lead to the current knowledge of HIT.
- Explain the nature of the antigen that causes production of HIT antibodies.
- Discuss the steps involved when HIT antibodies cause platelet activation.
- Explain the timeline of HIT.
- Describe the transient nature of HIT antibodies.
- Briefly outline differences in HIT positivitiy between various patient groups.
- Discuss the morbidity and mortality of patients affected with HIT.
- Recognize common nomenclature used to describe HIT in the literature.
- List clinical symptoms of HIT.
- Discuss the variability in platelet ‘alert’ values for suspect HIT cases.
- Briefly discuss the thrombosis risk in a HIT positive patient.
- List other complications that may alert medical staff to a positive HIT patient.
- Briefly describe the methodology used for various HIT assays.
- List the pros and cons of each assay type.
- Explain the difference between HIT and non-immune thrombocytopenia.
- Discuss the possible mechanisms that cause delayed-reaction HIT.
- List alternative anticoagulants suitable for HIT positive patients.
- List treatment options that should avoided in HIT patients.
Author/Instructor: Linda Stang, MLT
Version Date: December 2008